| Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. | |
| | |
MedLine Citation:
|
PMID: 19449121 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To perform a retrospective review of long-term outcome for patients with a first episode of acute urinary retention (AUR) who could void successfully after the initial trial without catheter (TWOC) after treatment with an alpha-adrenergic receptor blocker (AR blocker). METHODS: The records of 248 patients who presented with a first episode of AUR secondary to benign prostatic hyperplasia (BPH) and who could void successfully after the initial TWOC following treatment with an AR blocker were reviewed during the period January 1998 to December 2001. The characteristics of the patients and the subsequent outcomes were recorded. The primary outcome assessed was failed medical treatment within the five-year follow-up period. Factors correlated with the primary outcome were also assessed. RESULTS: For these 248 patients, the median follow-up time was 33.0 months (range 0-96 months). The percentage of patients with failed medical treatment at 6, 12, 24, and 60 months was 11.6, 14.3, 28.4, and 50.5%, respectively. Multivariate analysis indicated that only a prostate size >50 ml and serum prostate specific antigen (PSA) level during AUR >10 ng/dl were significant predictors of subsequent requirement for surgical intervention after a successful TWOC. CONCLUSIONS: Although AR blockers increased the success rate of TWOC, approximately half of the patients in this study still required additional intervention within five years. By using appropriate selection criteria, such as a large prostate size (>50 ml) or high serum PSA level during AUR (>10 microg/l), patients who are at greater risk of TWOC failure can be identified, and earlier surgical intervention can be offered to them. |
| | |
Authors:
|
K L Lo; M C K Chan; A Wong; S M Hou; C F Ng |
Publication Detail:
|
Type: Journal Article Date: 2009-05-16 |
Journal Detail:
|
Title: International urology and nephrology Volume: 42 ISSN: 1573-2584 ISO Abbreviation: Int Urol Nephrol Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-25 Completed Date: 2010-06-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0262521 Medline TA: Int Urol Nephrol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 7-12 Citation Subset: IM |
Affiliation:
|
Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adrenergic alpha-Antagonists / therapeutic use* Aged Aged, 80 and over Humans Male Middle Aged Prostatic Hyperplasia / complications*, drug therapy* Remission Induction Retrospective Studies Time Factors Treatment Outcome Urinary Retention / drug therapy*, etiology* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic alpha-Antagonists |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The lack of correlation between mast cells and microvessel density with pathologic feature of renal ...
Next Document: Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats.